The US CDMO market is racing past $39 billion as sponsors reshore from China \u2014 here’s who actually has the capacity to deliver in 2026.<\/p>\n\n\n\n
The US pharmaceutical CDMO market is projected to hit $72.98 billion by 2035, up from roughly $39.13 billion in 2025 \u2014 and sponsors are increasingly choosing where they manufacture based on more than price. Policy pressure on Chinese providers has pushed many Western sponsors to rethink dependence on Chinese manufacturing, accelerating a shift of capacity toward the US, Europe, South Korea, and India. For procurement teams evaluating capacity right now, here’s who’s actually positioned to deliver.<\/p>\n\n\n\n
Thermo Fisher’s Patheon network remains one of the deepest US CDMO footprints, with biopharma revenue projected between $42.4 and $43.3 billion. Its scale spans small molecule, biologics, and sterile fill-finish.<\/p>\n\n\n\n
Lonza anchors the top tier of biologics manufacturing, maintaining a 99% molecule retention rate \u2014 a meaningful reliability signal for sponsors weighing technical risk.<\/p>\n\n\n\n
Now under Novo Holdings ownership, Catalent continues to operate one of the largest integrated US manufacturing networks spanning biologics, cell and gene therapy, and drug-device combination products.<\/p>\n\n\n\n
The South Korean giant made a decisive US move with a $280 million acquisition of a Rockville, Maryland facility \u2014 its first major US production base \u2014 while its global capacity has reached 845,000 liters.<\/p>\n\n\n\n
Despite strong technical capability, WuXi carries policy exposure US sponsors need to factor into risk planning given ongoing legislative scrutiny of Chinese biomanufacturing providers.<\/p>\n\n\n\n
A major biologics-focused CDMO with growing US capacity, positioned as a Western alternative amid the geopolitical rebalancing reshaping sourcing decisions.<\/p>\n\n\n\n
A domestically-focused biomanufacturing platform built specifically around US supply security \u2014 increasingly relevant as reshoring accelerates.<\/p>\n\n\n\n
Pfizer’s internal CDMO arm brings big-pharma manufacturing rigor to outside sponsors, offering APIs and sterile injectables backed by established validation and technology-transfer practices.<\/p>\n\n\n\n
PCI recently committed over $365 million in combined US and EU facility investments, including a large-scale drug-delivery and combination-product expansion in Rockford, Illinois.<\/p>\n\n\n\n
A 40-plus-year API-focused CDMO with deep US regulatory experience, particularly strong for sponsors needing reliable small-molecule and IND-stage support.<\/p>\n\n\n\n
Capacity is tightening, not loosening.<\/strong> The top 19 CDMO players account for only half of FDA approvals since 2015 \u2014 meaning due diligence on modality-specific capacity matters more than brand recognition alone.<\/p>\n\n\n\n Geography is now a risk variable, not just a cost one.<\/strong> Sponsors weighing Chinese CDMOs against US\/EU alternatives need to factor policy exposure into total cost of ownership, not just per-unit pricing.<\/p>\n\n\n\n Lock in capacity early for complex modalities.<\/strong> ADC and bispecific programs face a genuine manufacturing bottleneck \u2014 sponsors should secure partners earlier in development than they would for a standard antibody program.<\/p>\n\n\n\n A Contract Development and Manufacturing Organization provides both process development and physical drug manufacturing services to pharmaceutical and biotech sponsors, without owning the drug itself.<\/p>\n\n\n\n Policy pressure on Chinese manufacturers, combined with sponsor demand for supply-chain resilience, has accelerated reshoring toward US, EU, and South Korean facilities.<\/p>\n\n\n\n Beyond price, sponsors should weigh modality-specific experience, facility capacity, regulatory track record, and geographic\/geopolitical exposure \u2014 particularly for complex biologics and combination products.<\/p>\n\n\n\n BioMed Nexus, The Top Biologics CDMOs in 2026<\/p>\n\n\n\n IntuitionLabs, Top CDMO Companies 2026<\/p>\n\n\n\n Towards Healthcare, U.S. Pharmaceutical CDMO Market Report<\/p>\n\n\n\n GM Insights, Pharmaceutical CDMO Market Size Report<\/p>\n\n\n\n PharmaSource, Top CDMOs in the United States by Facilities<\/p>\n\n\n\n CDMOWorld, Top Pharmaceutical CDMO Companies 2026<\/p>\n","protected":false},"excerpt":{"rendered":" The US CDMO market is racing past $39 billion as sponsors reshore from China \u2014 here’s who actually has the<\/p>\n","protected":false},"author":2,"featured_media":2528,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"colormag_page_container_layout":"default_layout","colormag_page_sidebar_layout":"default_layout","footnotes":""},"categories":[35,38],"tags":[],"class_list":["post-2527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-manufacturing","category-market-reports"],"magazineBlocksPostFeaturedMedia":{"thumbnail":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-150x150.png","medium":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-300x167.png","medium_large":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-768x429.png","large":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-1024x572.png","1536x1536":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026.png","2048x2048":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026.png","colormag-highlighted-post":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-392x272.png","colormag-featured-post-medium":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-390x205.png","colormag-featured-post-small":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-130x90.png","colormag-featured-image":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-800x445.png","colormag-default-news":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-150x150.png","colormag-featured-image-large":"https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-1376x600.png"},"magazineBlocksPostAuthor":{"name":"Robert Gultig","avatar":"https:\/\/secure.gravatar.com\/avatar\/c20cbbd071ef54879ba94b4792661d7a5bc956f295f336a9341672d77ad7092f?s=96&d=mm&r=g"},"magazineBlocksPostCommentsNumber":"0","magazineBlocksPostExcerpt":"The US CDMO market is racing past $39 billion as sponsors reshore from China \u2014 here’s who actually has the","magazineBlocksPostCategories":["Manufacturing","Market Reports"],"magazineBlocksPostViewCount":14,"magazineBlocksPostReadTime":3,"magazine_blocks_featured_image_url":{"full":["https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026.png",1376,768,false],"medium":["https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-300x167.png",300,167,true],"thumbnail":["https:\/\/pharmacta.kinsta.cloud\/wp-content\/uploads\/2026\/08\/Top-10-US-Pharma-Manufacturers-CDMOs-Ranked-2026-150x150.png",150,150,true]},"magazine_blocks_author":{"display_name":"Robert Gultig","author_link":"https:\/\/pharmacta.kinsta.cloud\/author\/robertgultigoq3w"},"magazine_blocks_comment":0,"magazine_blocks_author_image":"https:\/\/secure.gravatar.com\/avatar\/c20cbbd071ef54879ba94b4792661d7a5bc956f295f336a9341672d77ad7092f?s=96&d=mm&r=g","magazine_blocks_category":"Manufacturing<\/a> Market Reports<\/a>","videoUrl":"","_links":{"self":[{"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=\/wp\/v2\/posts\/2527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2527"}],"version-history":[{"count":2,"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=\/wp\/v2\/posts\/2527\/revisions"}],"predecessor-version":[{"id":2530,"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=\/wp\/v2\/posts\/2527\/revisions\/2530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=\/wp\/v2\/media\/2528"}],"wp:attachment":[{"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmacta.kinsta.cloud\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}FAQ<\/h3>\n\n\n\n
What is a CDMO?<\/h4>\n\n\n\n
Why are US CDMOs gaining market share?<\/h4>\n\n\n\n
How should sponsors evaluate CDMO partners?<\/h4>\n\n\n\n
Sources<\/h3>\n\n\n\n